Evidence map›Paper›PMID 24578952›Full record

ArticleCentral European journal of urology2012

HIF-1, GLUT1, endoglin, and BIRC5 expression in urine samples obtained from patients with bladder malignancies - after photodynamic diagnosis (PDD).

Michał Markowski, Marek Lipiński, Anna Krzeslak, Ewa Forma, Magdalena Bryś, Waldemar Różański

Abstract read
In one paragraph

Article in Central European journal of urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Michał MarkowskiClinic of Urology and Urological Oncology, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland.
Marek LipińskiClinic of Urology and Urological Oncology, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland.
Anna KrzeslakDepartment of Cytobiochemistry, University of Łódź, Łódź, Poland.
Ewa FormaDepartment of Cytobiochemistry, University of Łódź, Łódź, Poland.
Magdalena BryśDepartment of Cytobiochemistry, University of Łódź, Łódź, Poland.
Waldemar RóżańskiClinic of Urology and Urological Oncology, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland.
University of Łódź · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBladder cancer (BC) is a serious medical problem. The high rate of recurrence and progression demands the development of new methods, such as genetic markers, which allow diagnosis and patient follow-up.

objectivesThe aim of this study was to compare expression of HIF-1, GLUT1, endoglin, and BRIC5 in patients without and those with BC. The second group was divided into sub-groups: those without a history of PDD (photodynamic diagnosis) in the diagnostic process and those after PDD.

methodsPatients with BC were diagnosed using the PDD method using hexaminolevulinate (Hexvix(®)). The expressions of HIF-1, GLUT1, endoglin, and BRIC5 genes were established in urine specimens by real-time quantitative polymerase chain reaction (PCR).

resultsThe expressions of all tested genes were higher in the group of patients with BC than in the group without BC. In the group after PDD, a statistically significant overexpression of HIF-1 was observed. In this group, changes were not observed in cases of the other three tested genes.

conclusionsThe differences between the group with PDD and the group without it can be connected with the direct influence of PDD on malignant tissue, which can cause overexpression of HIF-1 only. This is, however, only a hypothesis and needs further study.

Indexed as

bladder cancergenetic markersphotodynamic diagnosis

Identifiers

PMID24578952
PMCPMC3921788
OpenAlexW2150551648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.